{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:44:38Z","timestamp":1775040278671,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Exacerbation triggered by respiratory infection is an important cause of morbidity and mortality in chronic obstructive pulmonary disease (COPD) patients. Strategies aiming to preventing infection may have significant public health impact. Our previous study demonstrated decreased immunological response to seasonal flu vaccination in COPD patients, questioning the efficiency of other vaccines in this group of patients. We performed a prospective, monocenter, longitudinal study that evaluated the humoral and cellular responses upon pertussis vaccination. We included 13 patients with stable COPD and 8 healthy volunteers. No difference in circulating B and T cell subsets at baseline was noted. Both groups presented similar levels of TFH, plasmablasts and pertussis specific antibodies induction after vaccination. Moreover, monitoring T cell immunity after ex-vivo peptide stimulation revealed equivalent induction of functional and specific CD4+\u2009T cells (IFN\u03b3, TNF\u03b1 and IL-2-expressing T cells) in both groups. Our results highlight the immunological efficiency of pertussis vaccination in this particularly vulnerable population and challenge the concept that COPD patients are less responsive to all immunization strategies. Healthcare providers should stress the necessity of decennial Tdap booster vaccination in COPD patients.<\/jats:p>","DOI":"10.1038\/s41598-023-38355-8","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T09:02:12Z","timestamp":1689757332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune response to pertussis vaccine in COPD patients"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-0850","authenticated-orcid":false,"given":"E.","family":"Feredj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Krief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Derumeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lacabaratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Leli\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"issue":"Suppl 2","key":"38355_CR1","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1513\/AnnalsATS.201503-126AW","volume":"12","author":"TA Bhat","year":"2015","unstructured":"Bhat, T. A., Panzica, L., Kalathil, S. G. & Thanavala, Y. Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 12(Suppl 2), S169-175 (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"38355_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson, G. C. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847\u2013852 (2002).","journal-title":"Thorax"},{"key":"38355_CR3","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","volume":"173","author":"A Papi","year":"2006","unstructured":"Papi, A. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173, 1114\u20131121 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38355_CR4","first-page":"409","volume":"2","author":"AJ Thorley","year":"2007","unstructured":"Thorley, A. J. & Tetley, T. D. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2, 409\u2013428 (2007).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"38355_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000354173","volume":"59","author":"R Shaykhiev","year":"2013","unstructured":"Shaykhiev, R. & Crystal, R. G. Innate immunity and chronic obstructive pulmonary disease: A mini-review. Gerontology 59, 481\u2013489 (2013).","journal-title":"Gerontology"},{"key":"38355_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1164\/rccm.200509-1461OC","volume":"174","author":"CS Berenson","year":"2006","unstructured":"Berenson, C. S. et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 174, 31\u201340 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38355_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(11)60988-4","volume":"378","author":"GG Brusselle","year":"2011","unstructured":"Brusselle, G. G., Joos, G. F. & Bracke, K. R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378, 1015\u20131026 (2011).","journal-title":"Lancet"},{"key":"38355_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0045-2017","volume":"26","author":"TMA Wilkinson","year":"2017","unstructured":"Wilkinson, T. M. A. Immune checkpoints in chronic obstructive pulmonary disease. Eur. Respir. Rev. 26, 170045 (2017).","journal-title":"Eur. Respir. Rev."},{"key":"38355_CR9","doi-asserted-by":"publisher","first-page":"CD002733","DOI":"10.1002\/14651858.CD002733.pub2","volume":"1","author":"PJ Poole","year":"2006","unstructured":"Poole, P. J., Chacko, E., Wood-Baker, R. W. B. & Cates, C. J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 1, CD002733. https:\/\/doi.org\/10.1002\/14651858.CD002733.pub2 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"key":"38355_CR10","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.jaci.2017.07.038","volume":"140","author":"A Parpaleix","year":"2017","unstructured":"Parpaleix, A. et al. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J. Allergy Clin. Immunol. 140, 1754-1757.e6 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"38355_CR11","unstructured":"https:\/\/vaccination-info.eu\/en\/disease-factsheets\/pertussis."},{"key":"38355_CR12","unstructured":"https:\/\/vaccination-info-service.fr\/Les-maladies-et-leurs-vaccins\/Coqueluche."},{"key":"38355_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/cid\/ciy889","volume":"69","author":"SA Mbayei","year":"2019","unstructured":"Mbayei, S. A. et al. Severe pertussis infections in the United States, 2011\u20132015. Clin. Infect. Dis. 69, 218\u2013226 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"38355_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/21645515.2019.1652517","volume":"16","author":"F Blasi","year":"2019","unstructured":"Blasi, F. et al. The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. Hum. Vaccine Immunother. 16, 340\u2013348 (2019).","journal-title":"Hum. Vaccine Immunother."},{"key":"38355_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMra1204186","volume":"368","author":"GJ Nabel","year":"2013","unstructured":"Nabel, G. J. Designing tomorrow\u2019s vaccines. N. Engl. J. Med. 368, 551\u2013560 (2013).","journal-title":"N. Engl. J. Med."},{"key":"38355_CR16","first-page":"335","volume":"202","author":"A Zhang","year":"2019","unstructured":"Zhang, A., Stacey, H. D., Mullarkey, C. E. & Miller, M. S. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J. I. 202, 335\u2013340 (2019).","journal-title":"J. I."},{"key":"38355_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1256427","volume":"346","author":"JM Fonville","year":"2014","unstructured":"Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996\u20131000 (2014).","journal-title":"Science"},{"key":"38355_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"38355_CR19","doi-asserted-by":"publisher","first-page":"198ra107","DOI":"10.1126\/scitranslmed.3006637","volume":"5","author":"MS Miller","year":"2013","unstructured":"Miller, M. S. et al. Neutralizing antibodies against previously encountered influenza virus strains increase over time: A longitudinal analysis. Sci. Transl. Med. 5, 198ra107 (2013).","journal-title":"Sci. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38355-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T09:33:32Z","timestamp":1689759212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38355-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38355"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38355-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2239513\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C has consultant arrangements and has received grants from Astra Zeneca, Boehringer Ingelheim, MSD, Pierre Fabre Oncology, Lilly, Roche, Bristol Myers Squibb, and Novartis. J.D.L has board membership with IVIR-AC Comitee WHO, Member of the French NITAG, Work package leader VRI (HIV vaccine-France), Work package leader EHVA project (HIV vaccine-EU), Work package leader Vaccelerate project (COVID19 vaccine-EU). The rest of the authors declare that they have no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests:"}}],"article-number":"11654"}}